MENU
FTXH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

FTXH stock forecast, quote, news & analysis

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for FTXH with price predictions
Nov 10, 2026

FTXH in upward trend: 10-day moving average crossed above 50-day moving average on October 20, 2026

The 10-day moving average for FTXH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FTXH as a result. In 67 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for FTXH just turned positive on October 15, 2026. Looking at past instances where FTXH's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.

FTXH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in 252 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 226 of 278 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for FTXH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 25 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 67 cases where FTXH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

FTXH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq U.S. Smart Pharmaceuticals TM Index. The fund will normally invest at least 80% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF is 77.04B. The market cap for tickers in the group ranges from 3.62B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is ELVN at 3.62B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 31%. For the same ETF, the average monthly price growth was 100%, and the average quarterly price growth was 407%. LQDA experienced the highest price growth at 22%, while CAI experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was -19%. For the same stocks of the ETF, the average monthly volume growth was 9% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 50
Price Growth Rating: 41
SMR Rating: 67
Profit Risk Rating: 56
Seasonality Score: 15 (-100 ... +100)